Exact Mass: 473.2236
Exact Mass Matches: 473.2236
Found 179 metabolites which its exact mass value is equals to given mass value 473.2236
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
CD 1790
CD 1790 is a metabolite of linagliptin. Linagliptin (BI-1356, trade names Tradjenta and Trajenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes. Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly. (Wikipedia)
Ala Pro Thr Trp
Ala Pro Trp Thr
Ala Gln Gln Gln
Ala Thr Pro Trp
Ala Thr Trp Pro
Ala Trp Pro Thr
Ala Trp Thr Pro
Asp Pro Arg Ser
Asp Pro Ser Arg
Asp Arg Pro Ser
Asp Arg Ser Pro
Asp Ser Pro Arg
Asp Ser Arg Pro
Phe Asn Pro Pro
Phe Pro Asn Pro
Phe Pro Pro Asn
Ile Met Asn Pro
Ile Met Pro Asn
Ile Asn Met Pro
Ile Asn Asn Asn
Ile Asn Pro Met
Ile Pro Met Asn
Ile Pro Asn Met
Leu Met Asn Pro
Leu Met Pro Asn
Leu Asn Met Pro
Leu Asn Asn Asn
Leu Asn Pro Met
Leu Pro Met Asn
Leu Pro Asn Met
Met Ile Asn Pro
Met Ile Pro Asn
Met Leu Asn Pro
Met Leu Pro Asn
Met Asn Ile Pro
Met Asn Leu Pro
Met Asn Pro Ile
Met Asn Pro Leu
Met Pro Ile Asn
Met Pro Leu Asn
Met Pro Asn Ile
Met Pro Asn Leu
Met Pro Gln Val
Met Pro Val Gln
Met Gln Pro Val
Met Gln Val Pro
Met Val Pro Gln
Met Val Gln Pro
Asn Phe Pro Pro
Asn Ile Met Pro
Asn Ile Asn Asn
Asn Ile Pro Met
Asn Leu Met Pro
Asn Leu Asn Asn
Asn Leu Pro Met
Asn Met Ile Pro
Asn Met Leu Pro
Asn Met Pro Ile
Asn Met Pro Leu
Asn Asn Ile Asn
Asn Asn Leu Asn
Asn Asn Asn Ile
Asn Asn Asn Leu
Asn Asn Gln Val
Asn Asn Val Gln
Asn Pro Phe Pro
Asn Pro Ile Met
Asn Pro Leu Met
Asn Pro Met Ile
Asn Pro Met Leu
Asn Pro Pro Phe
Asn Gln Asn Val
Asn Gln Val Asn
Asn Val Asn Gln
Asn Val Gln Asn
Pro Ala Thr Trp
Pro Ala Trp Thr
Pro Asp Arg Ser
Pro Asp Ser Arg
Pro Phe Asn Pro
Pro Phe Pro Asn
Pro Ile Met Asn
Pro Ile Asn Met
Pro Leu Met Asn
Pro Leu Asn Met
Pro Met Ile Asn
Pro Met Leu Asn
Pro Met Asn Ile
Pro Met Asn Leu
Pro Met Gln Val
Pro Met Val Gln
Pro Asn Phe Pro
Pro Asn Ile Met
Pro Asn Leu Met
Pro Asn Met Ile
Pro Asn Met Leu
Pro Asn Pro Phe
Pro Pro Phe Asn
Pro Pro Asn Phe
Pro Gln Met Val
Pro Gln Val Met
Pro Arg Asp Ser
Pro Arg Ser Asp
Pro Ser Asp Arg
Pro Ser Arg Asp
Pro Thr Ala Trp
Pro Thr Trp Ala
Pro Val Met Gln
Pro Val Gln Met
Pro Trp Ala Thr
Pro Trp Thr Ala
Gln Ala Gln Gln
Gln Met Pro Val
Gln Met Val Pro
Gln Asn Asn Val
Gln Asn Val Asn
Gln Pro Met Val
Gln Pro Val Met
Gln Gln Ala Gln
Gln Gln Gln Ala
Gln Val Met Pro
Gln Val Asn Asn
Gln Val Pro Met
Arg Asp Pro Ser
Arg Asp Ser Pro
Arg Pro Asp Ser
Arg Pro Ser Asp
Arg Ser Asp Pro
Arg Ser Pro Asp
Ser Asp Pro Arg
Ser Asp Arg Pro
Ser Pro Asp Arg
Ser Pro Arg Asp
Ser Arg Asp Pro
Ser Arg Pro Asp
Thr Ala Pro Trp
Thr Ala Trp Pro
Thr Pro Ala Trp
Thr Pro Trp Ala
Thr Trp Ala Pro
Thr Trp Pro Ala
Val Met Pro Gln
Val Met Gln Pro
Val Asn Asn Gln
Val Asn Gln Asn
Val Pro Met Gln
Val Pro Gln Met
Val Gln Met Pro
Val Gln Asn Asn
Val Gln Pro Met
Trp Ala Pro Thr
Trp Ala Thr Pro
Trp Pro Ala Thr
Trp Pro Thr Ala
Trp Thr Ala Pro
Trp Thr Pro Ala
NBD-FTY720 phenoxy
[1-[(2-methylpropan-2-yl)oxycarbonyl]-6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazine-1-carbonyl]indol-2-yl]boronic acid
[1-[(2-methylpropan-2-yl)oxycarbonyl]-5-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazine-1-carbonyl]indol-2-yl]boronic acid
4-[5-(2-chlorophenyl)-4-[4-(dimethylamino)phenyl]-oxazol-2-yl]-N,N-dipropyl-aniline
Simenepag isopropyl
C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent
2-imino-10-methyl-N-[2-(4-morpholinyl)ethyl]-5-oxo-1-(3-pyridinylmethyl)-3-dipyrido[3,4-c:1,2-f]pyrimidinecarboxamide
N-[4-[[5-(3-butyl-4-oxo-1,2-dihydroquinazolin-2-yl)-2-methoxyphenyl]methoxy]phenyl]acetamide
2-[2-[4-[2-Hydroxy-3-(2-methylphenoxy)propyl]-1-piperazinyl]ethyl]benzo[de]isoquinoline-1,3-dione
4-[2-[(1-acetyl-4-oxo-6-spiro[3,4-dihydro-2H-1-benzopyran-2,4-piperidine]yl)oxy]-1-oxoethyl]-1-piperazinecarboxylic acid ethyl ester
(3aR,4S,9bS)-4-(hydroxymethyl)-N-(2-methoxyphenyl)-8-(4-methoxyphenyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide
(3aS,4R,9bR)-4-(hydroxymethyl)-N-(2-methoxyphenyl)-8-(4-methoxyphenyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide
(2S,3S,3aR,9bR)-1-(cyclopropanecarbonyl)-2-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-3-(hydroxymethyl)-7-[(Z)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
(2R,3R,3aS,9bS)-1-(cyclopropanecarbonyl)-2-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-3-(hydroxymethyl)-7-[(Z)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
Usmarapride
Usmarapride (SUVN-D4010) is a potent, selective, orally active and brain penetrant 5-HT4 receptor partial agonist (EC50=44 nM). Usmarapride (SUVN-D4010) can be used for the research of cognitive deficits associated with Alzheimer's disease[1].